Fractyl Health, Inc. (GUTS) Stock Forecast
GUTS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.71 / 5 from 7 analysts
- Price target
- $53.28 average of analyst targets
- Upside to target
- +3,337.4% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-1.62
- 52-week range
- $1.55 – $28.44
GUTS analyst ratings
7 analystsNumber of analysts at each rating.
GUTS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GUTS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.47 | −$1.62 | −$1.32 | −$8.52 | +82.7% | 3 |
| Current fiscal year (FY2026) | −$3.94 | −$4.12 | −$3.72 | −$22.32 | +82.3% | 3 |
| Next fiscal year (FY2027) | −$4.59 | −$5.64 | −$3.48 | −$3.94 | −16.6% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GUTS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (FY2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (FY2027) | $4.5M | $0 | $12.9M | 0.0% | 4 |
GUTS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GUTS revenue: reported and forecast
GUTS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.66 | −$1.47 | −$1.47 | −$1.50 | −$1.47 | −11.2% | 0 up · 2 down |
| Current fiscal year (FY2026) | −$4.68 | −$3.96 | −$3.96 | −$3.98 | −$3.94 | −15.8% | 0 up · 2 down |
| Next fiscal year (FY2027) | −$5.98 | −$5.26 | −$5.26 | −$4.78 | −$4.59 | −23.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GUTS earnings surprises
Reported EPS vs the consensus estimate for the last 10 quarters; GUTS beat in 7 of 10.
What analysts expect from GUTS
7 analysts cover Fractyl Health; their consensus rating is strong buy (4.71 on a 1–5 scale, where 5 is a strong buy). The average price target is $53.28, 3,337.4% above the latest close of $1.55. Analysts expect earnings of −$3.94 per share for FY2026, +82.3% from a year earlier. For FY2027 the average estimate is −$4.59 per share on revenue of $4.5 million. Fractyl Health beat the EPS estimate in 7 of the last 10 quarters.
Related: GUTS income statement, GUTS key metrics, GUTS chart. See the GUTS stock overview for the latest quote and news.
GUTS forecast FAQ
What is Fractyl Health's price target?
The average analyst price target for Fractyl Health is $53.28, 3,337.4% above the latest close of $1.55.
Is Fractyl Health a buy, hold or sell?
Of 7 analysts covering Fractyl Health, 6 rate it a strong buy, 0 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Fractyl Health's EPS forecast?
Analysts forecast −$3.94 per share for FY2026 (range −$4.12 to −$3.72); for FY2027 the estimate is −$4.59.
When does Fractyl Health report earnings?
Fractyl Health is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 after the market closes; the EPS estimate is $-1.62.
Does Fractyl Health usually beat earnings estimates?
Fractyl Health reported EPS at or above the analyst estimate in 7 of the last 10 quarters.